Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:29203902  

Amniotic fluid stem cell-derived vesicles protect from VEGF-induced endothelial damage.

S Sedrakyan | V Villani | S Da Sacco | N Tripuraneni | S Porta | A Achena | M Lavarreda-Pearce | A Petrosyan | H Soloyan | R E De Filippo | B Bussolati | L Perin
Scientific reports | 2017

Injection of amniotic fluid stem cells (AFSC) delays the course of progression of renal fibrosis in animals with Alport Syndrome, enhancing kidney function and improving survival. The mechanisms responsible for these protective outcomes are still largely unknown. Here, we showed that vascular endothelial growth factor (VEGF) signaling within the glomeruli of Alport mice is strongly elevated early on in the disease, causing glomerular endothelial cell damage. Intraventricular injected AFSC that homed within the glomeruli showed strong modulation of the VEGF activity, particularly in glomerular endothelial cells. To investigate this phenomenon we hypothesized that extracellular vesicles (EVs) produced by the AFSC could be responsible for the observed renoprotection. AFSC derived EVs presented exosomal and stem cell markers on their surface membrane, including VEGFR1 and VEGFR2. EVs were able to modulate VEGF in glomerular endothelial cells by effectively trapping the excess VEGF through VEGFR1-binding preventing cellular damage. In contrast, VEGFR1/sVEGFR1 knockout EVs failed to show similar protection, thus indicating that VEGF trapping is a potentially viable mechanism for AFSC-EV mediated renoprotection. Taken together, our findings establish that EVs secreted by AFSC could target a specific signaling pathway within the glomerulus, thus representing a new potential glomerulus-specific targeted intervention.

Pubmed ID: 29203902

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Jackson Laboratory (tool)

RRID:SCR_004633

An independent, nonprofit organization focused on mammalian genetics research to advance human health. Their mission is to discover the genetic basis for preventing, treating, and curing human disease, and to enable research for the global biomedical community. Jackson Laboratory breeds and manages colonies of mice as resources for other research institutions and laboratories, along with providing software and techniques. Jackson Lab also conducts genetic research and provides educational material for various educational levels.

View all literature mentions

Ambion Inc. (tool)

RRID:SCR_008406

A division of Applied Biosystems selling products for the isolation, detection, quantification, amplification, and characterization of RNA.

View all literature mentions

RayBiotech (tool)

RRID:SCR_005517

An Antibody supplier

View all literature mentions

B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J (tool)

RRID:IMSR_JAX:007914

Mus musculus with name B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J from IMSR.

View all literature mentions

B6.Cg-Tg(Tek-cre)1Ywa/J (tool)

RRID:IMSR_JAX:008863

Mus musculus with name B6.Cg-Tg(Tek-cre)1Ywa/J from IMSR.

View all literature mentions